Objective

The objective of this study is to investigate the expression of Vascular cell adhesion molecule-1 (VCAM-1) and very late appearing antigen-4 (VLA-4) cytokines in MM (multiple Myeloma).

Method

Forty patients with MM are selected as the experimental group and 30 healthy persons as the control group. Flow cytometry is used to detect the expression of VCAM-1 (CD106), VLA-4 (CD49d), CD38 and CD138 antigens in experimental group and control group. ELISA (Enzyme Linked Immunosorbent Assay) is used to detect the concentration of VCAM-1 in serum of experimental group and control group. RT-PCR is used to detect the expression of VCAM-1.

Results

The positive rate and antigen expression rate of VACM-1 antigen in the experimental group were significantly higher than those in the control group (P < 0.05). There were statistical differences of VLA-4 and VCAM-1 antigens between the initial diagnosis group and the relapse/refractory group, and between the relapse/refractory group and the platform stage group (P < 0.05). There were significant differences between VLA-4 antigen and VACM-1 antigen, phase I and phase II, and between phase I and phase III (P < 0.05). The concentration of VCAM-1 and the expression of VCAM-1 mRNA in the experimental group were significantly higher than (P < 0.01). In the different stages of ISS (International Staging System) and different disease groups in the experimental group, the concentration of VCAM-1 and the expression level of VCAM-1 mRNA are significantly different among the three groups of stage I, II and III (P < 0.01). There is a significant difference between the initial diagnosis group, the relapse/refractory group and the platform group (P < 0.05).

Conclusion

There are abnormal expressions of adhesion molecules VCAM-1 and VLA-4 in multiple myeloma patients, which are related to ISS staging.

中文翻译：

---

VCAM-1和VLA-4细胞因子在多发性骨髓瘤中的表达及发病机制。

客观的

本研究的目的是研究血管细胞粘附分子-1 (VCAM-1) 和非常晚出现的抗原-4 (VLA-4) 细胞因子在 MM（多发性骨髓瘤）中的表达。

方法

选取40名MM患者作为实验组，30名健康人作为对照组。流式细胞仪检测实验组和对照组VCAM-1（CD106）、VLA-4（CD49d）、CD38和CD138抗原的表达。ELISA（酶联免疫吸附试验）用于检测实验组和对照组血清中VCAM-1的浓度。RT-PCR用于检测VCAM-1的表达。

结果

实验组VACM-1抗原阳性率和抗原表达率均显着高于对照组（P < 0.05）。VLA-4、VCAM-1抗原在初诊组与复发/难治组之间、复发/难治组与平台期组之间差异有统计学意义（P < 0.05）。VLA-4抗原与VACM-1抗原、I期与II期、I期与III期有显着差异（P < 0.05）。实验组VCAM-1浓度和VCAM-1 mRNA表达明显高于(P<0.01)。在ISS（国际分期系统）的不同阶段和实验组的不同疾病组中，I、II、III期三组间VCAM-1浓度和VCAM-1 mRNA表达水平有显着差异（P < 0.01）。初诊组、复发难治组和平台组比较差异有统计学意义（P < 0.05）。

结论

多发性骨髓瘤患者存在黏附分子VCAM-1、VLA-4的异常表达，与ISS分期有关。